Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Breast cancer entities : Novartis ag save search
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
Published: 2022-05-04 (Crawled : 08:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
kisqali novartis cancer breast cancer her2- her2
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Published: 2021-12-10 (Crawled : 13:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: -0.31%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
piqray novartis media cancer breast cancer her2- her2 metastatic breast cancer
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
Published: 2021-12-08 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
kisqali genomic cancer breast cancer her2- her2 metastatic breast cancer
Breast Cancer Drugs Global Market Report 2021
Published: 2021-11-12 (Crawled : 11:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
cancer drug cancer drug breast cancer market
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
media cancer breast cancer her2+ her2- her2
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Published: 2021-06-02 (Crawled : 14:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
media cancer breast cancer her2+ her2- her2 metastatic breast cancer
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Published: 2021-05-19 (Crawled : 22:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.46%
H: 1.21%
C: 0.78%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.12%
H: 3.3%
C: 2.08%
cancer breast cancer
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
Published: 2021-03-18 (Crawled : 12:30) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
women cancer breast cancer her2+ her2- her2
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
Published: 2021-03-16 (Crawled : 01:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.14%
H: 0.82%
C: 0.7%
CELC | $17.22 5.06% 4.82% 230K
|
Commercial Services
|
| O: 1.19%
H: 6.37%
C: 0.66%
new drug collaboration cancer biotech drug iot breast cancer trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.